JP2022513384A5 - - Google Patents

Info

Publication number
JP2022513384A5
JP2022513384A5 JP2021547665A JP2021547665A JP2022513384A5 JP 2022513384 A5 JP2022513384 A5 JP 2022513384A5 JP 2021547665 A JP2021547665 A JP 2021547665A JP 2021547665 A JP2021547665 A JP 2021547665A JP 2022513384 A5 JP2022513384 A5 JP 2022513384A5
Authority
JP
Japan
Prior art keywords
antibody
immunoconjugate
pharmaceutical composition
sequence
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547665A
Other languages
English (en)
Japanese (ja)
Other versions
JP7445995B2 (ja
JP2022513384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058066 external-priority patent/WO2020092155A1/en
Publication of JP2022513384A publication Critical patent/JP2022513384A/ja
Publication of JP2022513384A5 publication Critical patent/JP2022513384A5/ja
Priority to JP2024023003A priority Critical patent/JP7664660B2/ja
Application granted granted Critical
Publication of JP7445995B2 publication Critical patent/JP7445995B2/ja
Priority to JP2025060295A priority patent/JP2025106347A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547665A 2018-10-31 2019-10-25 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 Active JP7445995B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024023003A JP7664660B2 (ja) 2018-10-31 2024-02-19 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
JP2025060295A JP2025106347A (ja) 2018-10-31 2025-04-01 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862753498P 2018-10-31 2018-10-31
US62/753,498 2018-10-31
US201962798234P 2019-01-29 2019-01-29
US62/798,234 2019-01-29
US201962803060P 2019-02-08 2019-02-08
US62/803,060 2019-02-08
US201962822971P 2019-03-24 2019-03-24
US62/822,971 2019-03-24
US201962824014P 2019-03-26 2019-03-26
US201962823992P 2019-03-26 2019-03-26
US62/823,992 2019-03-26
US62/824,014 2019-03-26
PCT/US2019/058066 WO2020092155A1 (en) 2018-10-31 2019-10-25 Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024023003A Division JP7664660B2 (ja) 2018-10-31 2024-02-19 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用

Publications (3)

Publication Number Publication Date
JP2022513384A JP2022513384A (ja) 2022-02-07
JP2022513384A5 true JP2022513384A5 (https=) 2022-10-28
JP7445995B2 JP7445995B2 (ja) 2024-03-08

Family

ID=70463883

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021547665A Active JP7445995B2 (ja) 2018-10-31 2019-10-25 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
JP2024023003A Active JP7664660B2 (ja) 2018-10-31 2024-02-19 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
JP2025060295A Pending JP2025106347A (ja) 2018-10-31 2025-04-01 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024023003A Active JP7664660B2 (ja) 2018-10-31 2024-02-19 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
JP2025060295A Pending JP2025106347A (ja) 2018-10-31 2025-04-01 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用

Country Status (14)

Country Link
US (1) US20230192858A1 (https=)
EP (1) EP3873940A4 (https=)
JP (3) JP7445995B2 (https=)
KR (2) KR20230051630A (https=)
CN (1) CN112996813A (https=)
AU (3) AU2019371223B2 (https=)
BR (1) BR112021008060A2 (https=)
CA (1) CA3117700C (https=)
IL (3) IL321750A (https=)
MX (1) MX2021005048A (https=)
NZ (1) NZ775959A (https=)
SG (1) SG11202104373YA (https=)
TW (1) TWI863938B (https=)
WO (1) WO2020092155A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
CA3122773A1 (en) 2018-12-26 2020-07-02 Xilio Development, Inc. Anti-ctla4 antibodies and methods of use thereof
CN113924118A (zh) * 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
UA128549C2 (uk) * 2019-12-27 2024-08-07 Чугаі Сейяку Кабусікі Кайся Антитіло до ctla-4 та його застосування
CN116194480A (zh) 2020-08-13 2023-05-30 百时美施贵宝公司 将il-2重定向到目的靶细胞的方法
CN116390949A (zh) * 2020-11-06 2023-07-04 百时美施贵宝公司 作为单一疗法给药和施用非岩藻糖基化抗ctla-4抗体
EP4301467A1 (en) * 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
TWI879694B (zh) * 2021-06-25 2025-04-01 日商中外製藥股份有限公司 抗ctla-4抗體的用途
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
WO2024056049A1 (zh) * 2022-09-16 2024-03-21 同润生物医药(上海)有限公司 具有pH依赖性的抗CTLA4抗体或抗原结合片段
AU2024284619A1 (en) 2023-06-09 2025-12-04 Institut Gustave Roussy Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof
WO2025230706A1 (en) * 2024-04-29 2025-11-06 The Regents Of The University Of California Immune checkpoint inhibitors for use in cardiac repair

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US6981720B2 (en) * 2003-11-07 2006-01-03 Agilent Technologies, Inc. Tapered ceramic GC fitting and assembly
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2009131702A2 (en) * 2008-04-25 2009-10-29 Dyax Corp. Antibodies against fcrn and use thereof
MX349622B (es) * 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
KR20150008082A (ko) * 2012-04-27 2015-01-21 바이오아트라, 엘엘씨 수정된 항체 영역 및 그의 용도
US9540449B2 (en) * 2012-08-13 2017-01-10 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
WO2016036916A1 (en) * 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
EP3256165B1 (en) * 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
MA53355A (fr) * 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
US11542332B2 (en) * 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
JP7010854B2 (ja) * 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN110267990B (zh) * 2016-08-30 2023-11-07 Xencor股份有限公司 结合共刺激性和检查点受体的双特异性免疫调节抗体
US20180339043A1 (en) * 2017-05-26 2018-11-29 Janux Therapeutics, Inc. Modified antibodies
KR102834864B1 (ko) * 2018-02-02 2025-07-16 온코씨4, 아이앤씨. 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체

Similar Documents

Publication Publication Date Title
JP2022513384A5 (https=)
IL321750A (en) Anti-ctla4 antibodies, antibody fragments, immunoconjugates thereof and their uses
JP7335290B2 (ja) 二重特異性四価抗体並びにその製作及び使用方法
JP2020524174A5 (https=)
JP2024125370A (ja) クローディン１８．２結合部分およびその利用
US10253095B2 (en) Anti-KIR combination treatments and methods
KR102805258B1 (ko) Pd-l1에 친화성을 갖는 신규 폴리펩티드
JP2022542222A5 (https=)
JP2020513855A5 (https=)
JP2020524675A5 (https=)
CA3148329A1 (en) Targeted immunotolerance with a pd-1 agonist
JP2017513900A5 (https=)
JP2018501197A5 (https=)
JP2018502050A5 (https=)
JP2017523786A5 (https=)
RU2009114161A (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
RU2011110405A (ru) Агенты, связывающие рецептор frizzled и их применение
JP2005505256A5 (https=)
Schlereth et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
CN112601522A (zh) 抗体-alk5抑制剂偶联物及其用途
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
KR20240157789A (ko) 면역 항원 특이적 il-18 면역사이토카인 및 이의 용도
JP2026053733A (ja) チェックポイント分子に対する多重特異性結合性構築物およびその使用
JP2025509824A5 (https=)
JP2021519319A5 (https=)